Patent Application
20230321122
The present disclosure is directed to an active agent for use in hair growth regulation, particularly for use in the treatment of hair growth, wherein the active agent modulates the activity of an ion channel, including but not limited to activation, enhancement, inactivation or blocking an ion channel or dampening the cellular response induced by an ion channel or interfering with the expression of the ion channel.
Further, the present disclosure is directed to a composition for use as a cosmetic or medicament in the treatment of hair growth, the composition comprising at least one active agent that modulates the activity of an ion channel, including but not limited to activation, enhancement, inactivation or blocking an ion channel or dampening the cellular response induced by an ion channel or interfering with the expression of the ion channel.
In addition, the present disclosure is directed to a non-therapeutic method of hair growth regulation, wherein an effective amount of at least one active agent that modulates the activity of an ion channel, including but not limited to activation, enhancement, inactivation or blocking an ion channel or dampening the cellular response induced by an ion channel or interfering with the expression of the ion channel, is administered to a subject.
The formation of hair follicles occurs once in the lifetime of healthy mammals, with the number of hair follicles determined in utero. Hair follicle morphogenesis is the generation of the whole hair follicle structure from the epidermis and the mesoderm. During postnatal life the hair follicle undergoes life-long cyclical transformations where it progresses through stages of rapid growth (anagen), regression (catagen) and relative quiescence (telogen) classified by morphological indicators and molecular markers.
There are a number of common and rare diseases associated with the hair follicle cycle, such as non-scarring alopecia, scarring alopecia, chronic and acute hair shedding, hypertrichosis or hirsutism. Further, there are a number of other conditions, where the control of unwanted hair on the human body or the promotion of hair growth on areas of the human body is desired, such as with drug-induced hair loss (e.g., chemotherapy), radiation-induced hair loss (e.g., radiotherapy) and with unwanted hair growth due to drugs such as cyclosporine A or diazoxide.
There is a continuous need for active agents for actively controlling hair growth in subjects without undesired side effects.
It was found that the transient receptor potential ion channel TRPM5 is expressed in hair follicles. Specifically, strong cytoplasmic expression was detected in the outer root sheath (ORS), whereas a weaker expression was found in the inner root sheath (IRS). The dermal sheath (DS) and the dermal papilla (DP) did not show TRPM5 expression.
“Ion channels” are pore-forming proteins located in biological membranes. Through the pores of the proteins ions may pass the membrane down their electrochemical gradient. By either opening or closing the pore ion channels are capable of gating and controlling the flow of ions across the membranes thereby modulating the intracellular concentrations of ions. Alteration of intracellular ion concentrations affect a plethora of cellular responses and processes including, but not limited to, e.g., growth, differentiation, survival, death, mediator release, immune mechanisms, etc.
“Transient receptor potential channels” (TRP channels) are a group of ion channels located mostly on the plasma membrane, and there are about 30 TRP channels including TRPC, TRPV, TRPM, TRPN, TRPA, TRPP and TRPML. The ion channels have a relatively non-selective permeability to cations, including sodium, calcium and magnesium.
“TRPM5” is the official gene symbol for “transient receptor potential cation channel subfamily M member 5” and identifies the protein that is encoded by the TRPM5 gene in humans (NCBI Gene ID: 29850; HGNC: 14323; NCBI mRNA sequence: NM_014555.3; NCBI protein sequence: NP_055370.1; Status on Jun. 7, 2020).
It has been found that the pheromones 2-heptanone (in the following referred to as “2-Hep”) and 2,5-dimethylpyrazine (in the following referred to as “DMP”), both of which being agonists of the transient receptor potential ion channel TRPM5, causing the channel to be open, maintained ex vivo human hair growth. Indeed, the number of hair follicles that remained in anagen during the 7-day-long culturing was higher in the pheromone treated groups than in the control ones. In addition, treatment of hair follicles with 2-Hep resulted in the elevation of intrafollicular expression of AXIN2 (known promoter of hair growth) and the suppression of level of TGFβ2 (known inhibitor of hair growth).
Vice versa, inhibition of TRPM5 using the selective inhibitor triphenylphosphine oxide (TPPO) consistently promoted catagen in human hair follicle (HF) organ culture. Likewise, specific knock-down of TRPM5 by RNA silencing (thereby mimicking of inhibition of TRPM5 coupled signaling) reduced cell proliferation in hair matrix and proximal bulb, characteristics of hair growth inhibition. In addition, knock-down of TRPM5 by RNA silencing induced a tendency of apoptosis. Finally, knock-down of TRPM5 by RNA silencing resulted in the suppression of intrafollicular expressions of LEF1 and IGF1 (known promoters of hair growth) and the elevation of levels of TGFβ2 and SFRP1 (known inhibitors of hair growth).
In addition to the above active agents, a number of additional active agents have been identified acting on TRPM5 and, thus, being suitable for use in the treatment of hair growth.
Concluding, the present disclosure is characterized by an active agent for use in the treatment of hair growth, wherein the active agent activates, enhances, inactivates or blocks TRPM5 or dampens the cellular response induced by the transient receptor potential ion channel TRPM5 or interferes with the expression of the ion channel.
According to one alternative of the present disclosure, the active agent that activates, enhances, inactivates or blocks the ion channel or dampens the cellular response induced by the transient receptor potential ion channel TRPM5 is an agonist or antagonist of the ion channel.
As referred to herein, an “agonist” of the transient receptor potential ion channel TRPM5 is a substance that binds to the ion channel and activates or enhances the ion channel thereby augmenting the cellular response linked to TRPM5.
As referred to herein, an “antagonist” of the transient receptor potential ion channel TRPM5 is a substance that binds to the ion channel and blocks TRPM5 thereby dampening the cellular response to an agonist rather than activating or enhancing it like an agonist.
An “inverse agonist” of the transient receptor potential ion channel TRPM5 is a substance that binds to the ion channel and in turn induces an opposite the cellular response than seen when applying an agonist.
With respect to the transient receptor potential ion channel TRPM5 of the present disclosure, the term “cellular response” is primarily to be understood as a change of ion concentration in the cell being the result of an agonist/antagonist/inverse agonist binding to the transient receptor potential ion channel TRPM5. However, the term also encompasses instances, where the binding of an agonist/antagonist/inverse agonist induces a cellular response without altering the intracellular ion concentration.
Accordingly, an inventive agonist of the transient receptor potential ion channel TRPM5 activates or enhances the ion channel to produce the cellular response like an endogenous agonist does, whereas the inventive antagonist of the ion channel blocks or dampens the ion channel to produce the cellular response as usually activated/enhanced by an endogenous agonist, and the inventive inverse agonist modulates the ion channel to produce the opposite cellular response as usually activated/enhanced by endogenous agonists.
In those embodiments, where the active agent is an agonist of the transient receptor potential ion channel TRPM5, the active agent is used in the treatment of unwanted hair loss. In those embodiments, where the active agent is an antagonists/inverse agonists of the transient receptor potential ion channel TRPM5, the active agent is used in the treatment of unwanted hair growth.
In specific embodiments of the present disclosure, the ion channel agonist/antagonist/inverse agonist used is a TRPM5 agonist selected from the group comprising dimethylpyrazine, dimethylethylpyrazine, tetramethylpyrazine, 2-heptanone, eugenol, SID2848719 (CAS number 702636-90-6, SMILES, NC(═O)C1(CCN(CC1)S(═O)(═O)c1ccc2OCCCOc2c1)N1CCCCC1), rutamarin, bergapten, xanthotoxin, isopimpinellin, carbachol, 3-deoxyglucosone, glucagon-like peptide 1, (E)-N-(3,4 dimethoxybenzylidene)-2-naphthalene-1-yl)acetohydrazide, or a combination thereof. Alternatively, the TRPM5 agonist is an aptamer binding to the TRPM5 ion channel and activating or enhancing the ion channel to produce the cellular response.
The term “aptamer,” as used herein, refers to DNA, RNA or XNA oligonucleotide or peptide molecules that bind to a specific target molecule, such as ion channel molecules.
In other embodiments of the present disclosure, the ion channel agonist/antagonist/inverse agonist used is a TRPM5 antagonist/inverse agonist selected from triphenylphosphine oxide, econazole, miconazole, chlorpromazine, or combinations thereof. Alternatively, the TRPM5 antagonist/inverse agonist is an aptamer binding to the TRPM5 ion channel and inactivating, blocking or dampening the ion channel to produce the cellular response.
According to an alternative of the present disclosure, an active agent that interferes with the expression of the ion channel TRPM5 is used in hair growth regulation. An active agent that interferes with the expression of the ion channel TRPM5 is either miRNA, siRNA or a ribozyme targeted to the TRPM5 gene or targeted to the mRNA corresponding to the TRPM5 gene.
The term “miRNA” refers to microRNA, i.e., small non-coding RNA molecules containing 21 to 23 nucleotides and functioning in RNA knock-down and post-transcriptional regulation of gene expression. miRNAs function via base-pairing with complementary sequences within mRNA molecules. As a result, these mRNA molecules are knocked-down, by cleavage, destabilization and/or less efficient translation of the mRNA.
The term “siRNA” refers to small interfering RNA, i.e., small non-coding RNA molecules, 20 to 25 base pairs in length. siRNA interferes with the expression of specific genes with complementary nucleotide sequences by degrading mRNA after transcription, thereby preventing translation.
According to the present disclosure, a gene is “targeted” by a miRNA, siRNA or a ribozyme when the miRNA, siRNA or a ribozyme molecule selectively decreases or inhibits the expression of TRPM5. The phrase “selectively decrease or inhibit,” as used herein, refers to miRNA, siRNA or a ribozyme that affects the expression of TRPM5.
In specific embodiments of the present disclosure, miRNA or siRNA interfere with the gene expression of the ion channel TRPM5 by hybridizing under stringent conditions to the gene transcript, i.e., the TRPM5 mRNA, wherein hybridizing “under stringent conditions” means annealing to the target mRNA region, under standard conditions, e.g., high temperature (e.g., <60° C. for 2 hours) and/or low salt content (e.g., 0.1×SSC) that tend to disfavor hybridization.
According to the present disclosure, one of the above-mentioned active agents is used in the treatment of hair growth. In specific embodiments of the present disclosure, the treatment is effected locally, i.e., in, on or at the skin area to be treated. In some embodiments of the present disclosure, the treatment is effected topically, wherein the term “topical” refers to a medication that is applied to a particular place on the skin and/or its appendages, such as hair. In specific embodiments, the topical application is epicutaneous, meaning that the agonist or antagonist is applied directly to the skin. In other embodiments of the present disclosure, the treatment is effected transdermally, wherein the term “transdermal” refers to a medication that is applied across the Stratum corneum into the deeper skin layers, e.g., by injection with a standard needle or microneedles. In other embodiments of the present disclosure, the treatment is effected transappendageally, wherein the term “transappendageal” refers to an applied medication that is permeating the skin via skin appendage structures (such as the hair follicles, sebaceous glands, and sweat glands) into the deeper skin layers.
The term “treatment,” as used herein, refers to any action resulting in the change of a physical condition. Particularly, the “treatment of hair growth” refers to any change of an initial hair growth condition, such as unwanted presence of hair, unwanted lack of hair, unwanted slow/fast hair growth, chemotherapy-related hair loss, drug-related hair growth and radiation-related hair loss. In other words, the present disclosure is directed to any kind of hair growth regulation.
In specific embodiments of the present disclosure, the above-mentioned active agent is used as a cosmetic in the treatment of hair growth. Particularly, the use as a cosmetic occurs non-therapeutically, but in order to achieve a change of an initial hair growth condition, such as unwanted presence of hair, unwanted lack of hair, unwanted slow/fast hair growth, wherein the initial condition is not caused by a disease or disorder.
In those embodiments, where the above mentioned active agent is used as a cosmetic, the active agent used should be cosmetically acceptable, wherein “cosmetically acceptable” means that the active agent should not be toxic or harmful or have any other detrimental side effects upon application on hair and/or skin.
In other specific embodiments of the present disclosure, the above mentioned active agent is used as a medicament in the topical treatment of hair growth disorder, wherein the term “disorder” refers to any functional abnormality or disturbance of the normal healthy condition, and the term “medicament” refers to a substance useful in curing, treating or preventing a condition of disorder.
In some embodiments, the above mentioned active agent is used as a medicament in the topical treatment of a hair growth disorder being selected from the group comprising nonscarring (non cicatricial) alopecia, such as alopecia areata, telogen effluvium, androgenetic alopecia, anagen effluvium, loose anagen syndrome and female pattern hair loss; scarring (cicatricial) alopecia, such as cutaneous lichen planopilaris, frontal fibrosing alopecia, discoid lupus erythematosus, dissecting cellulitis and folliculitis decalvans; and excessive hair growth such as hypertrichosis and hirsutism.
In those embodiments, where the above mentioned active agent is used as a medicament, the active agent used should be pharmaceutically acceptable, wherein “pharmaceutically acceptable” means that the active agent should not be toxic or harmful or have any other detrimental side effects upon application on hair and/or skin.
In some embodiments, at least one of the inventive active agents is used as an ingredient of a composition for use as a cosmetic or medicament in the topical treatment of hair growth; the composition further comprising at least one auxiliary agent selected from the group comprising carriers, excipients, adjuvants, diluents, and disintegrants.
In specific embodiments of such compositions, the auxiliary agent is selected from the group comprising liposomes, nanoparticles, carboxymethyl cellulose, hydroxyethyl cellulose, mineral oil, petrolatum, glycerin, polysorbate 80, hydroxyethyl starch, dextran, and polyethylene glycol.
In the inventive compositions, the concentration of the active agent usually is in the range of from 10 μM to 10,000 μM. In some embodiments, the lower limit for the concentration of the active agent is 30 μM or even 100 μM. In some embodiments, the upper limit is 3,000 μM or 1.000 μM. This results in preferred ranges of e.g., from 30 μM to 10,000 μM, from 30 μM to 3,000 μM, from 10 μM to 3,000 μM, 100 μM to 3,000 μM and the like.
In specific embodiments, such compositions further comprise at least one other active agent being effective in the treatment of hair growth.
In such embodiments, the other active agent may be selected from hair growth inhibitors, such as inhibitors of ornithine decarboxylase (including difluoromethylornithine (DFMO)), antiandrogen compounds, inhibitors of 5-α-reductase, inhibitors of androgen ion channel, inhibitors of S-adenosyl methionine decarboxylase, inhibitors of γ-glutamyl transpeptidase, inhibitors of adenylosuccinate synthetase, inhibitors of aspartate transcarbamylase, inhibitors of transglutaminase, inhibitors of L-asparagine synthetase, pantothenic acid and its analogues, sulfhydryl reactive compounds, inhibitors of lipoxygenase, inhibitors of cyclooxygenase, inhibitors of nitric oxide synthetase, inhibitors of ornithine amino transferase, inhibitors of cysteine synthesis pathway enzymes, inhibitors of protein kinase C, catechin compounds, green tea polyphenols, non-steroidal angiogenesis suppressors, inhibitors of arginase, inhibitors of the metabolic pathway for the conversion of glucose to acetyl-CoA, compounds that inhibit the formation of glycoprotein, proteoglycans, and glycosaminoglycans, inhibitors of matrix metalloproteinase, inhibitors of the cholesterol synthesis pathway, inhibitors of DNA topoisomerase, inhibitors of aminoacyl-tRNA synthetase, inhibitors of the hypusine biosynthesis pathway, compounds that activate androgen conjugation, inhibitors of alkaline phosphatase, inhibitors of protein tyrosine kinase, and compounds that increase cellular ceramide levels. Specific examples include cyproterone acetate, progesterone, acivicin, anthglutin, L-alanosine, guanidino-succinic acid, ethacrynic acid, D-pantothenic acid, pantoyl alcohol, gabaculin, canaline, isonicotinic acid, verapamil, phentolamine, pentosan polysulfate, nafoxidine, tripelennamine, octapine, phloretin, argaric acid, simvastatin, atorvastatin, lovastatin, fluvastatin, mevastatin, NG-methyl-L-arginine, NG-nitro-L-arginine, benzoyl-L-argininamide, L-argininamide, quercetin, apigenin, nordihydroguaratic acid (NDGA), ketoprofen, naproxen, tolmetin, diclofenac, diflunisal, sulindac, thiosalicylic acid, cysteamine, diethyldithiocarbamic acid, D-penicillamine, N-acetyl-L-cysteine, bathocuproine, enalapril, tamoxifen, cimetidine, mycophenolic acid, tetracycline, doxycycline, minocycline, thioridazine, trifluoperizine, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine, glycyrrhetinic acid, epigallocatechin gallate, epicatechin gallate, epigallocatechin, epicatechin, fusidic acid, and nitroso-acetyl-penicillamine.
In yet other embodiments, the other active agent may be selected from preventatives of chemotherapy- or radiation-induced alopecia or hair loss, such as 4-((cyanoimino((1,2,2-trimethylpropyl)amino)methyl)amino)benzonitrile, epidermal growth factor, fibroblast growth factors, including but not limited to keratinocyte growth factor (FGF7), prostaglandins, cyclin dependent kinases, p53 inhibitors, capase-3 inhibitors, N-acyl cysteine, parathyroid hormone antagonist, alpha-tocopherol, cyclosporine, angiotensin ion channel blockers, and minoxidil.
Generally, the inventive composition may be used in any formulation suitable for treatment of hair growth. In specific embodiments of the present disclosure, the composition is formulated in the form of an ointment, a lotion, a cream, a shampoo, a gel, a spray, a plaster or a sustained release plaster. In other specific embodiments of the present disclosure, the composition is formulated in the form of a solution. The solution may be applied by means of a microneedle device or prior to sonication, electrical stimulation, etc.
As mentioned above, the inventive use of the above mentioned active agent may also occur non-therapeutically, wherein non-therapeutically refers to a treatment not being directed to curing, treating or preventing a condition of disorder (see above).
Therefore, the present disclosure is further directed to a non-therapeutic method of hair growth regulation, wherein an effective amount of at least one of the above mentioned active agent is administered to a subject.
The non-therapeutic method also encloses embodiments, where the above mentioned active agent is administered to the subject to be treated simultaneously, sequentially or separately together with at least one other active agent useful in the treatment of hair growth (see above).
The following examples show some of the features of specific embodiments of the present disclosure. However, the skilled reader will understand that those embodiments are just exemplary but do not restrict the inventive idea to exactly the features or the combination of features of the embodiments of the examples.
In the description of the examples it is referred to the following figures, wherein:
1. Immunofluorescence Analysis of TRPM5 Expression in Human Skin
Cryosection without fixation was dried and then fixed in acetone at −20° C. Slides were then washed in phosphate-buffered saline (PBS). Sample sections were pre-treated with goat serum. Anti-TRPM5 was added to sample sections and incubated. Slides were washed in PBS and goat anti-rabbit-A488 antibody was added to sample sections and incubated. Slides were washed in PBS and sample sections were incubated with DAPI. Slides were washed again in PBS and mounted with coverslip using Southernbiotech FLUOROMOUNT®.
2. Inactivation of TRPM5 by RNAi Knockdown
For analyzing the effect of inactivating TRPM5 by RNAi knock-down, human hair follicles were transfected with 1 μM TRPM5-targeting Accell siRNA (siTRPM5) and scrambled siRNA (siScr). After 24 hours, transfected hair follicles were snap frozen in liquid nitrogen for immunofluorescence analysis or collected in RNA extraction buffer for RNA isolation. TRPM5 protein expression was detected as above. Ki67 protein expression was detected as for TRPM5 using mouse anti-human Ki67 primary antibody and goat anti-mouse-A568 secondary antibody. For TUNEL immunolabelling, hair follicle cryosections were fixed in formalin/ethanol/acetic acid and labeled with digoxigenin-deoxyUTP (APOPTAG® Fluorescein In Situ Apoptosis detection kit; Millipore) in the presence of terminal deoxynucleotidyl transferase according to the manufacturer's protocol. TUNEL+ cells were visualized with anti-digoxigenin FITC-conjugated antibody (APOPTAG® kit). Cells positive for Ki-67 or TUNEL were counted per hair matrix and ORS and were normalized to the total number of nuclei (DAPI+).
Total RNA was isolated using PICOPURE® RNA Isolation Kit (Applied BioSystems) according to the manufacturer's protocol. After isolation, 100 ng of total RNA was reverse-transcribed into cDNA using a TETRO® cDNA synthesis kit (Bioline). Quantitative-PCR was performed using the StepOne Plus real time PCR system (Applied Biosystems) using TAQMAN® fast advanced master mix and TAQMAN® probes for LEF1, IGF1, TGFB2 AND SFRP1 (Applied Biosystems). The amount of the aforementioned transcripts was normalized to the expression of reference gene (GAPDH) using the ΔΔCt method. Results were performed in triplicate for each experiment.
According to
3. Activation of TRPM5 with 2,5-Dimethylpyrazine (DMP)
Human anagen hair follicles were isolated from the skin of males undergoing hair transplantation with written informed consent. Microdissected hair follicles were amputated at the level of dermal-subcutaneous junction and equilibrated in Williams' E medium (WEM) (Life Technologies) supplemented with 2 mM L-glutamine (Life Technologies), 10 ng/ml hydrocortisone, 10 μg/ml insulin, and antibiotics (all from Sigma-Aldrich). After 24 hours, growing undamaged anagen hair follicles were selected for treatment with DMP Human hair follicles were cultured in presence of DMP (12.5 The culture medium was changed every two days with addition of DMP. Hair follicles were photographed and percentage of hair follicles at different stages of hair cycle were calculated at day 3 and day 6 of the treatment and compared to vehicle.
According to the graph shown in
4. Activation of TRPM5 with 2-Heptanone (2-Hep)
Human anagen hair follicles were isolated from the skin of males undergoing hair transplantation with written informed consent. Microdissected hair follicles were amputated at the level of dermal-subcutaneous junction and equilibrated in Williams' E medium (WEM) (Life Technologies) supplemented with 2 mM L-glutamine (Life Technologies), 10 ng/ml hydrocortisone, 10 μg/ml insulin, and antibiotics (all from Sigma-Aldrich). After 24 hours, growing undamaged anagen hair follicles were selected for treatment with 2-Hep (12.5 The culture medium was changed every two days with addition of 2-Hep. Hair follicles were photographed and percentage of hair follicles at different stages of hair cycle were calculated at day 3 and day 6 of the treatment and compared to vehicle.
According to the graph shown in
For gene expression analysis, human hair follicles were microdissected as above and treated with 2-Hep (12.5 uM) for 6 hours. Following the treatment, total RNA was isolated and processed for cDNA synthesis as above. Quantitate PCR was performed using TAQMAN® assay with probes for TGFB2 and AXIN2 (Applied Biosystems).
5. Inactivation of TRPM5 with Triphenyl Phosphine Oxide (TPPO)
Human anagen hair follicles were isolated from the skin of males undergoing hair transplantation with written informed consent. Microdissected hair follicles were amputated at the level of dermal-subcutaneous junction and equilibrated in Williams' E medium (WEM) (Life Technologies) supplemented with 2 mM L-glutamine (Life Technologies), 10 ng/ml hydrocortisone, 10 μg/ml insulin, and antibiotics (all from Sigma-Aldrich). After 24 hours, growing undamaged anagen hair follicles were selected for treatment with human hair follicles were cultured in presence of TPPO (150 The culture medium was changed every two days with addition of TPPO. Hair follicles were photographed and percentage of hair follicles at different stages of hair cycle were calculated at day 3 and day 6 of the treatment and compared to vehicle.
According to the graph shown in
For gene expression analysis, human hair follicles were microdissected as above and treated with TPPO (150 uM) for 6 hours. Following the treatment, total RNA was isolated and processed for cDNA synthesis as above. Quantitate PCR was performed using TAQMAN® assay with probes for IGF1, FGF7 and TGFB2 (Applied Biosystems).
| Number | Date | Country | Kind |
|---|---|---|---|
| 20193431.2 | Aug 2020 | EP | regional |
This application is a national phase entry under 35 U.S.C. § 371 of International Patent Application PCT/EP2021/072990, filed Aug. 19, 2021, designating the United States of America and published as International Patent Publication WO 2022/043171 A1 on Mar. 3, 2022, which claims the benefit under Article 8 of the Patent Cooperation Treaty to European Patent Application Serial No. 20193431.2, filed Aug. 28, 2020.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2021/072990 | 8/19/2021 | WO |
